PYRUKYND 5mg (Mitapivat Tablet) 5mg

Mitapivat, sold as Pyrukynd 5mg, is an oral tablet used for hemolytic anemia management. This prescription medication helps regulate red blood cell production. Store below 25°C and keep out of reach of children. Always follow healthcare provider guidance when using this treatment.

Strength

5mg

Pack Size

56s

Storage

Below 25°C

Manufacturer / TM Owner

Agios Pharmaceuticals Inc

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Mitapivat 5mg tablets are prescribed to treat hemolytic anemia, a condition where red blood cells are destroyed faster than they can be made. It may be used for adults with certain types of anemia, including sickle cell disease or pyruvate kinase deficiency. This medication helps improve red blood cell survival and function.

Side Effects

Common effects of mitapivat include headache, nausea, and fatigue. Some patients report dizziness or mild digestive discomfort when starting treatment. These effects are typically temporary and may lessen over time as the body adjusts to the medication.

Precautions & Warnings

Keep Pyrukynd 5mg tablets in their original packaging and store below 25°C. Avoid exposure to moisture or direct sunlight. Inform your healthcare provider about all medications and supplements you are taking before starting mitapivat. Regular blood tests may be required to monitor your response to treatment.

Avoid Interactions

Mitapivat may interact with strong CYP3A inhibitors or inducers, affecting its effectiveness. Avoid grapefruit products while taking this medication, as they can alter drug metabolism. Discuss alcohol use with your doctor, as it may influence treatment outcomes. Always review your full medication list with a healthcare professional.

Frequently Asked Questions

Mitapivat is used to treat hemolytic anemia in adults, including conditions like pyruvate kinase deficiency or sickle cell disease.

Store the tablets below 25°C in their original packaging, away from moisture and direct sunlight.

Always inform your doctor about all medications and supplements you are taking before starting mitapivat.

Common side effects may include headache, nausea, fatigue, dizziness, or mild digestive discomfort.

Avoid grapefruit products while taking mitapivat, as they may affect how the medication works.

Editorial & Trust Signals

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical wholesaler & exporter

Last updated: 17 Jun 2026

References

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.